Oncology News | pharmaphorum

News

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

News

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.

News

International cancer experts have called for big changes to bile duct cancer, which kills three-quarters of patients within a year of diagnosis.